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Abstract
Bisphenol-A (BPA) is one of the most widespread endocrine disrupting chemicals (EDC) used as the base compound in the
manufacture of polycarbonate plastics. Although evidence points to consider exposure to BPA as a risk factor for insulin
resistance, its actions on whole body metabolism and on insulin-sensitive tissues are still unclear. The aim of the present
work was to study the effects of low doses of BPA in insulin-sensitive peripheral tissues and whole body metabolism in adult
mice. Adult mice were treated with subcutaneous injection of 100 mg/kg BPA or vehicle for 8 days. Whole body energy
homeostasis was assessed with in vivo indirect calorimetry. Insulin signaling assays were conducted by western blot analysis.
Mice treated with BPA were insulin resistant and had increased glucose-stimulated insulin release. BPA-treated mice had
decreased food intake, lower body temperature and locomotor activity compared to control. In skeletal muscle, insulin-
stimulated tyrosine phosphorylation of the insulin receptor b subunit was impaired in BPA-treated mice. This impairment
was associated with a reduced insulin-stimulated Akt phosphorylation in the Thr
308 residue. Both skeletal muscle and liver
displayed an upregulation of IRS-1 protein by BPA. The mitogen-activated protein kinase (MAPK) signaling pathway was also
impaired in the skeletal muscle from BPA-treated mice. In the liver, BPA effects were of lesser intensity with decreased
insulin-stimulated tyrosine phosphorylation of the insulin receptor b subunit. In conclusion, short-term treatment with low
doses of BPA slows down whole body energy metabolism and disrupts insulin signaling in peripheral tissues. Thus, our
findings support the notion that BPA can be considered a risk factor for the development of type 2 diabetes.
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Introduction
The incidence of Type 2 diabetes mellitus is growing and
millions of people are diagnosed with this metabolic disorder every
year. The characteristic features of this disease include glucose
intolerance, insulin resistance in skeletal muscle, adipocytes and
liver, and often compensating hyperinsulinemia at the onset of this
pathology. At later stages, b-cell function is affected leading to a
decrease in insulin release and lower levels of plasma insulin,
which favors hyperglycemia. Insulin resistance can develop in
response to the environment and results from a complex interplay
between nutrient overload, systemic excess of fatty acids, adipose
tissue inflammation and oxidative stress [1]. In recent years, the
life style in the modern society has drastically changed, with
increased consumption of fat-rich food and sedentary activities
among other factors. Thus, nowadays, an excessive caloric intake
and an inadequate physical activity have become the most
important players in the development of insulin resistance [2].
In addition, exposure to endocrine disrupting chemicals (EDCs)
resulting from life style changes, such as consumption of canned
food or drinks, as well as food embedded in plastics, was also
proposed to be involved in the etiology of insulin resistance and
associated metabolic disorders [3–5]. Recently, considerable
attention has been given to the endocrine disruptor bisphenol-A
(BPA), since epidemiological studies in humans have associated
bisphenol-A exposure with an increased risk of adverse health
effects including diabetes and insulin resistance [6–8]. BPA, which
possesses xenoestrogenic activity [9], is currently used as the base
compound in the manufacture of polycarbonate plastic and the
resin lining of food beverage cans as well as in drinking water
bottles and stores [10]. A large number of in vivo and in vitro studies
have reported adverse effects of BPA and a significant number of
these were performed below the predicted ‘‘safe’’ reference dose of
50 mg/kg/day, established by the U.S.-EPA [6]. Importantly, this
safe exposure level is 1,000 times lower than the amount found to
produce the lowest adverse effect for BPA in laboratory animals
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(50 mg/kg per day).
Recently, pharmacokinetic experiments performed in monkeys
indicated that BPA exposure may be much higher than initially
thought [11] and exposure may originate from sources other than
food, i.e, skin absorption [12,13]. BPA exposure has already been
demonstrated to be widespread as it was found in more than 93%
of USA citizens [14] and its concentration in blood reaches 1–
18 nM [6].
Studies in rodents have demonstrated that exposure to BPA as
well as other EDCs elicits alterations in glucose homeostasis [15–
18]. We have previously shown that BPA has a direct effect on
pancreatic b-cells potentiating glucose-stimulated insulin secretion,
which favors postprandial hyperinsulinemia as well as insulin
resistance [9,19]. Remarkably, insulin resistance appeared when
mice were exposed to BPA orally or by subcutaneous injection
[15]. In addition to a direct modulation of pancreatic b-cell
function, BPA exposure also involves actions on peripheral
metabolic tissues [15,16]. In the present study, we confirm our
previous results regarding the potential diabetogenic effect of BPA
on glucose homeostasis and we further demonstrate that eight days
treatment with low doses of BPA alters whole body energy
homeostasis and impairs insulin action in skeletal muscle and liver.
Thus, the present results indicate that BPA disrupts insulin
signaling in peripheral tissues and is likely a risk factor for the
development of type 2 diabetes.
Materials and Methods
Animals and treatment
The ethical committee of Miguel Hernandez University
‘‘Comisio ´n de E ´tica en la Investigacio ´n Experimental’’ specifically
reviewed and approved this study (approval ID: INA-AN-001-07).
Experiments were performed with 3 months old male Swiss albino
OF1 mice that were individually maintained under standard
housing conditions. BPA was dissolved in tocopherol-stripped corn
oil and administered subcutaneously during 8 days twice a day
(9:00 a.m. and 2:00 p.m.). Control mice were injected with 100 ml
of vehicle at the same time-points. The total daily dose used for
BPA was 100 mg/kg.
Plasma analysis
To measure plasma metabolites blood samples were collected
from the tail vein. Insulin was measured by enzyme-linked
immunosorbent assay (Mercodia, Crystal Chem, Sweden) and
NEFA was measured using a commercial kit (WakoH; Richmond,
USA).
Glucose and insulin tolerance test
For glucose tolerance tests, animals were fasted overnight for
12 hr, and blood samples were obtained from the tail vein.
Animals were then injected intraperitoneally with 2 g/kg body
weight of glucose, and blood samples were taken at the indicated
intervals. For insulin tolerance tests, fed animals were used.
Animals were injected intra-peritoneally with 0.75 IU/kg body
weight of soluble insulin. Blood glucose was measured in each
sample using an Accu-check compact glucometer (Roche, Madrid,
Spain).
Insulin secretion measurement
Pancreatic islets of Langerhans were isolated by collagenase
digestion of the pancreas. For static incubations, four islets from
each experimental group were first incubated for 30 min at 37uC
in Krebs–bicarbonate (KBR) buffer with the following composi-
tion: NaCl 115 mmol/L, KCl 5 mmol/L, CaCl2 2.56 mmol/L,
MgCl2 1 mmol/L, NaHCO3 10 mmol/L, HEPES 15 mmol/L,
supplemented with 5.6 mmol/L glucose, 3 g of BSA/L, and
equilibrated with a mixture of 95% O2/5% CO2 to obtain a
pH=7.4. This medium was then replaced with fresh buffer and
the islets were incubated for 1 h with 2.8 and 16.7 mmol/L
glucose. At the end of the incubation period, the supernatant was
collected and insulin content measured by RIA.
Western Blot
Insulin signaling experiments were conducted by western blot
analysis. Briefly, mice were fasted overnight and received a single
intraperitoneal injection of 100 ml (10
26 M) insulin [20] Tissues
were harvested 5 min later. Gastrocnemius muscles and liver were
homogenized in ice-cold buffer (Tris pH 7.5 100 mmol/L, sodium
pyrophosphate 10 mmol/L, sodium fluoride 100 mmol/L, EDTA
10 mmol/L, sodium vanadate 10 mmol/L, PMSF 2 mmol/L and
Triton X-100 1%) for 20 sec. Homogenates were softly agitated
for 1 h at 4uC and subjected to centrifugation (14000 g for
40 min) at 4uC. Protein content in lysates was measured by the
biuret dye method. For insulin receptor (IR) immunoprecipitation
experiments, samples containing approximately 2 mg of protein
were incubated with 10 ml of rabbit polyclonal anti-IR-b (SC-711,
Santa Cruz, CA, USA) and incubated overnight at 4uC. Protein-
antibody complexes were separated using protein A-sepharose
(Amersham, Uppsala, Sweden), treated with Laemmli sample
buffer containing dithiothreitol, then heated at 95uC for 5 min and
loaded into 10% polyacrylamide gels. For experiments with total
protein extracts, 70 mg were loaded into 10% gels. Following
electrophoresis, proteins were transferred to nitrocellulose mem-
branes and incubated overnight with blocking buffer (5% non-fat
dried milk, Tris 10 mmol/L, NaCl 150 mmol/L, and Tween-20
0.05%). Membranes were then probed with primary antibodies
against phosphotyrosine (SC-508), phospho Akt (Threonine
308 and
Serine
473) (SC-16646-R, SC-7985-R, Santa Cruz, CA, USA),
phospho ERK (SC-7383, Santa Cruz, CA, USA), and Phospho-
inositide 3-kinase regulatory subunit (p85) (06-496, Upstate, Santa
Cruz, NY, USA). Antibodies anti-Akt (SC-8312), anti-IRS-1 (SC-
560; Santa Cruz, CA, USA) and anti-ERK (SC-135900, Santa
Cruz, CA, USA) were used to normalize phosphorylated proteins.
For total protein content, a-tubulin (SC-8035, Santa Cruz, CA,
USA) was used as an internal control. Detection was performed
using enhanced chemiluminescence (SuperSignal West Pico,
Pierce, Rockford, IL, USA) after 2 h incubation with a horseradish
peroxidase-conjugated secondary antibody (1:10,000, Invitrogen,
Sa ˜o Paulo, SP, BRA). Band intensities were quantified by optical
densitometry (Scion Image, Frederick, MD, USA).
Whole-Body Energy Homeostasis
Eleven to twelve BPA- and vehicle-treated mice were analyzed
for energy expenditure, (respiratory quotient) RQ, and locomotor
activity using a custom-made calorimetry system (LabMaster; TSE
Systems). The instrument consists of a combination of highly
sensitive feeding and drinking sensors for automated online
measurement. The calorimetry system is an open-circuit system
that determines O2 consumption, CO2 production, and RQ. A
photobeam-based activity monitoring system detects and records
every ambulatory movement, including rearing and climbing
movements, in every cage. Lights were on from 7 am until 7 pm.
Habituation to the metabolic cages consisted of 4 days of
adaptation, after which animals were brought to normal cages
during 3 days. For the analysis, animals were put back into
metabolic cages for 48 h. The last 24 h, corresponding to the eight
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used for data collection.
Statistical analysis
Data is shown as mean 6 SEM. Student’s t test, one-way or
two-way ANOVA were performed as appropriate with a level of
significance p,0.05.
Results
BPA treatment impairs glucose homeostasis in adult
mice and increase glucose-stimulated insulin secretion
To examine the effect of BPA on whole body metabolic
parameters, we treated mice by subcutaneous injection of either
corn oil vehicle or BPA at doses of 100 mg/kg/day for 8
consecutive days. BPA treatment for 8 days had no effect on
body weight (Figure S1). Blood glucose levels were similar during
fasting but decreased in the fed state in mice treated with BPA
(Figure 1A). Lipid metabolism was likely unaltered in vehicle and
BPA-treated mice since they presented similar levels of plasma
non-esterified fatty acids (NEFA, Figure 1B). Plasma insulin in the
fed state showed an increase in the BPA treated mice (p=0.05)
(Figure 1C).
We have previously shown that 4 days of treatment with 17b-
estradiol or BPA at a dose of 100 mg/kg/day increase insulin
content and release from pancreatic b-cells. Here, we confirm the
hyperinsulinemic effect of BPA showing that eight days of
treatment also led to an increase of glucose-stimulated insulin
secretion (GSIS) in isolated islets (Figure 1D). Notably, basal
insulin secretion was inhibited by BPA treatment (Figure 1D).
These results strengthen the idea that BPA has a direct effect on
pancreatic b-cells by increasing glucose-stimulated insulin secre-
tion.
BPA treatment alters whole body energy homeostasis in
adult mice
We next analyzed whether BPA treatment alters in vivo glucose
and insulin tolerance (Figure 2). Whereas glucose clearance was
similar between both groups upon glucose administration
(Figure 2A), BPA-treated mice had reduced insulin sensitivity in
comparison to control mice when insulin tolerance tests were
performed (Figure 2B). To determine whether BPA treatment had
an effect on metabolism, the respiratory exchange ratio (RER),
was measured by indirect calorimetry over 24 h. This is a numeric
index of carbohydrate and fat utilization based on a ratio of
carbon dioxide produced to oxygen consumed. RER was
unchanged between vehicle and BPA-treated mice (Figure 2C).
The diurnal pattern of food intake was similar between vehicle and
BPA-treated mice whereas the nocturnal pattern of food intake
was decreased (p=0.05) in BPA-treated mice (Figure 2D).
Importantly, the diurnal and nocturnal 24-h rhythm of spontane-
ous locomotor behaviour was decreased in BPA-treated mice
comparing to controls (Figure 2E). The decreased energy
expenditure was also evident in BPA-treated mice (Figure 2F).
These results demonstrate that BPA treatment leads to impair-
ments in insulin action and alterations in whole-body energy
homeostasis.
BPA treatment alters insulin signaling in the skeletal
muscle
Since treatment of BPA during adulthood leads to alterations in
insulin action (Figure 2B), we next studied the insulin signaling
pathways in the skeletal muscle of mice treated with BPA. In basal
conditions, BPA treatment induced a 2-fold increase in the IRS-1
protein expression compared to vehicle (Figure 3A). The
downstream pathways of the insulin receptor such as phospho-
inositide 3-kinase (PI3K) subunit p85 (Figure S2A) and Akt protein
expression were not affected by BPA-treatment in skeletal muscles
(Figure 3B). Our results indicate that BPA treatment upregulates
IRS-1 protein expression in skeletal muscle in basal conditions.
We next verified whether BPA treatment affects insulin
signaling pathways in insulin stimulated conditions. Intraperito-
neal insulin injection stimulated tyrosine phosphorylation in
skeletal muscle from mice treated with vehicle within 5 minutes
(Figure 3C), reflecting the physiological nature of the insulin
stimulation. In contrast, insulin stimulation elicited a lower level of
tyrosine phosphorylation of the insulin receptor b subunit in the
skeletal muscle from BPA-treated mice (Figure 3C). Akt/PKB is a
protein downstream mediator of PI3K that plays a important role
in insulin stimulation of glucose transport. We assessed the most
important phosphorylation sites of Akt protein involved in glucose
uptake in skeletal muscle. Insulin-stimulated Akt phosphorylation
in the Ser
473 residue was similar in skeletal muscle from vehicle
and BPA-treated mice (Figure 3D). Interestingly, Akt phosphor-
ylation in the Thr
308 was decreased (p=0.05) in the skeletal
muscle from BPA-treated mice (Figure 3E). These results indicate
that short-treatment with BPA alters insulin signaling in skeletal
muscles, which might contribute to the insulin resistance found in
these mice.
The mitogen-activated protein kinase (MAPK) signaling
pathway plays an important role in cell growth, proliferation,
and differentiation in skeletal muscle and it is regulated by insulin
as well. We next checked whether BPA treatment could affect the
MAPK pathway in skeletal muscles. Figure 3F shows that basal
ERK phosphorylation was similar between vehicle and BPA-
treated mice. As expected, insulin increased the phosphorylation of
ERK in the vehicle (Figure 3F). In contrast, insulin was not able to
increase ERK phosphorylation in the muscles from BPA-treated
mice (Figure 3F). These results show that BPA can impair insulin-
stimulated MAPK signaling pathway. Thus, BPA downregulates
multiple sites in the insulin signaling cascade in skeletal muscles.
BPA treatment alters insulin signalling in the liver
Insulin action in the liver is essential to shutdown the hepatic
glucose production during postprandial states to control glucose
homeostasis. As observed in the muscle, BPA treatment led to an
upregulation of IRS-1 protein expression (Figure 4A), and did not
affect PI3K subunit p85 (Figure S2B) and Akt protein expression
(Figure 4B) in basal conditions in the liver. Impairments in the
insulin signaling pathway were evident in liver from BPA-treated
mice only at the level of the tyrosine phosphorylation of the insulin
receptor b subunit, which was less phosphorylated upon insulin
administration in BPA-treated mice in comparison to controls
(Figure 4C). However, unlike in the skeletal muscle, downstream
pathways in the insulin signaling remained unaffected by BPA
treatment. Insulin-stimulated Akt phosphorylation in the Ser
473
and Thr
308 residue were similar in livers from vehicle and BPA-
treated mice (Figure 4D and 4E). No differences were observed in
the mitogen-activated protein kinase signaling in both basal and
insulin stimulated conditions in livers from vehicle and BPA-
treated mice (Figure 4F). We also investigated the effect of BPA
treatment on pyruvate-induced gluconeogenesis by performing a
pyruvate tolerance test. As shown in Figure S3, pyruvate tolerance
was unaltered. These results show that BPA treatment can also
downregulate part of the insulin signaling in the liver. Nonetheless,
the insulin resistance observed in BPA-treated mice is mainly
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Discussion
In the present study we demonstrate that exposure to low doses
of BPA during adulthood promotes adverse effects on glucose
homeostasis and insulin action on peripheral tissues with the
concomitant risk of developing type 2 diabetes.
Mice treated with BPA during 8 days presented no increase in
weight and normal non-esterified fatty acids (NEFA) levels;
however they presented insulin resistance and had a strong
tendency to be hyperinsulinaemic in the fed state, together with
decreased glucose levels. The hyperinsulinaemia in the fed state
may be explained by an improved stimulus secretion coupling of
b-cells, because islets isolated from BPA treated mice displayed a
greater release of insulin in response to high glucose. The
stimulatory action of BPA on islets may be due to an adaptation
to the peripheral insulin resistance or to a direct action of BPA on
b-cells or both. In any case, a direct action of BPA is very likely
because it has been demonstrated in isolated islets from mice and
rats that low doses of BPA potentiates GSIS [19,21] as well as
pancreatic insulin content [19]. Fluvestran blocks BPA action on
GSIS pointing to an involvement of estrogen receptors [21].
Figure 1. In vivo parameters and glucose stimulated insulin secretion in vehicle and BPA-treated mice for 8 days. (A) Blood glucose
levels in fasted and fed state (n=7–9), (B) Plasma non-esterified fatty acids (NEFA) (n=7–9). (C) Plasma insulin (n=6–8). (D) Glucose-induced insulin
secretion in isolated islets from vehicle and BPA treated mice. Isolated islets were incubated with 2.8 or 16.7 mM glucose for 1 hour (n=12). Statistical
differences were determined by Student’s t test *, p,0.05. Data are expressed as mean 6S.E.M.
doi:10.1371/journal.pone.0033814.g001
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PLoS ONE | www.plosone.org 4 March 2012 | Volume 7 | Issue 3 | e33814Figure 2. BPA treatment leads to insulin resistance and impairments in whole-body energy homeostasis. (A) Intraperitoneal glucose
tolerant test in mice treated with vehicle or BPA. Plasma glucose concentration during the ipGTT (n=7–8). (B) Intraperitoneal insulin tolerant test.
Plasma glucose concentration during the ipITT (n=7–8). (C) Respiratory exchange ratio (RER) assed over 24 h (n=6). (D) Food Intake assed over 24 h
(n=6) (E) Ambulatory Activity assed over 24 h (n=6). (F) Body temperature assed over 24 h (n=6). Statistical differences were determined by
Student’s t test *, p,0.05; **, p,0.01. Data are expressed as mean 6S.E.M.
doi:10.1371/journal.pone.0033814.g002
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involves ERb [22]. The use of antiestrogens as well as estrogen
receptor knockout mice indicates that the regulation of pancreatic
insulin gene expression and content by BPA and Estradiol (E2) is
dependent of the estrogen receptor ERa [19]. These actions of
ERa involve a nonclassical mechanism, initiated outside the
nucleus with ERK1/2 activation [19]. Downstream of ERK1/2,
the activation of the transcription factor NeuroD1 regulates insulin
gene transcription [23]. The estrogenic action of BPA through
extranuclear ERa is initiated at concentrations as low as 1 nM,
indicating that via this nonclassical estrogen activated pathway,
BPA is as potent as the natural hormone E2 [19]. Estrogen
receptors are essential molecules involved in glucose homeostasis
and energy balance [24–26]. Using genetic rescue of nonclassical
ERa signalling in ERa2/2 mice, it has been demonstrated that
energy homeostasis is greatly controlled by nonclassical ERa
activated pathways [27]. Then, it is plausible that the effects of
BPA on energy balance, glucose homeostasis and insulin sensitivity
described in the present work are, at least in part, mediated by
ERa in a nonclassical manner. Nevertheless, an action of BPA on
ERb, G protein-coupled receptor 30 (GPR30) or estrogen-related
receptor c (ERRc) cannot be ruled out at the present moment
[24,28–30].
In the present work, BPA treatment led to changes in whole-
body energy homeostasis. Mice treated with BPA showed the same
levels of RER indicating that 8 days treatment may not be enough
to change the use of substrate for energy. However, BPA treatment
led to lower energy intake (measured by food consumption) and
lower energy expenditure (measured by locomotor activity and
heat production). Notably, body weight was unchanged. These
changes could be explained by a direct effect of BPA on the central
nervous system, because estrogen signaling modifies leptin and
insulin responses and decreases food intake [31]. This may occur
through the hypothalamus, since estrogen alters melanocortin cells
rewiring and modulate energy balance [32,33]. Similarly, other
endocrine disruptors such as soy-derived isoflavones alter energy
balance in association with changes in Agouti related Protein
(AgRP) expression in the hypothalamus [34]. Nevertheless, a direct
effect of BPA in other tissues cannot be excluded. We have
recently shown that mice treated with BPA during pregnancy have
increased leptin levels compared to controls at the end of
pregnancy [16]. It is plausible that BPA could directly increase
leptin levels through a direct action on adipocytes, since it can alter
the release of adiponectin [35]. This could explain the decreased
food intake found in our experiments with BPA-treated mice. In
any case, we cannot rule out a CNS-related behavioral effect
associated with BPA exposure; reduced food intake and locomotor
activity may reflect lethargy. Overall, these results indicate that
BPA treatment alters energy metabolism in mice.
Type 2 diabetes mellitus is characterized by insulin resistance,
which results in lower levels of insulin-induced blood glucose
uptake into target tissues. Here we showed that BPA disrupts
insulin signaling in skeletal muscle and liver. In response to insulin,
autophosphorylation of the insulin receptor (IR) is decreased in
both skeletal muscle and liver by BPA treatment when compared
to controls. Downstream Akt phosphorylation on Thr
308 was,
however, only decreased in skeletal muscles.
Several studies have provided evidence for defects in the insulin
signaling in human skeletal muscle from obese and type 2 diabetes
subjects using in vitro and in vivo approaches [36]. Our results in the
skeletal muscle showed that BPA treatment led to decreased IR
tyrosine phosphorylation, which was followed by reduced Akt
phosphorylation on Thr
308. However, comparable levels on
insulin-induced Ser
473 phosphorylation were detected in vehicle
and BPA-treated mice. These observations are in agreement with
similar studies in skeletal muscle from type 2 diabetic patients
showing decreased insulin-induced Akt phosphorylation on Thr
308
and similar levels of insulin-induced Ser
473 phosphorylation [37].
Apart from its effects via Akt, insulin also activates the MAP kinase
pathway to increase cell growth, proliferation, and differentiation
[38,39]. It has been shown that skeletal muscles from obese and
type 2 diabetic subjects have normal insulin stimulation of the
MAP kinase pathway [38]. Here we show that BPA-treatment
impairs insulin-induced ERK phosphorylation in skeletal muscle.
In adult animals, an increase in skeletal muscle mass occurs mainly
as a result of an increase in the size rather than the number of
muscle fibres and is generally thought to be regulated by the Akt/
mTOR pathway [40]. Although the role that ERK1/2 activation
may have in skeletal muscle it is still greatly unknown, this pathway
is related with the increase in the expression of L-type amino acid
transporter LAT2 after RSK1/2 phosphorylation [41]. In
addition, ERK1/2 activation upregulates leptin receptor expres-
sion in C2C12 myotubes [42]. The decrease of insulin-induced
ERK1/2 phosphorylation described here is an interesting finding
that indicates a new potential deleterious effect of BPA on MAP
kinase pathway, which is absent in obesity and type 2 diabetes but
may be related to leptin resistance in skeletal muscle among other
deleterious actions.
The effects of BPA treatment were less severe in the liver than in
the skeletal muscle. In the liver, impairments of insulin signaling
were only present at the level of IR phosphorylation. The normal
insulin-stimulated Akt phosphorylation and ERK might be due to
a compensation mechanism as a consequence of the upregulation
of IRS-1. BPA treatment causes upregulation of IRS-1 protein
expression in the absence of insulin in both tissues. This may
counteract the diminished phosphorylation of the insulin receptor
in the liver, avoiding insulin resistance. In skeletal muscle,
although there is up regulation of IRS-1 at the basal level, this
may not be powerful enough to counteract the BPA-decreased
autophosphorylation of the insulin receptor, which is stronger in
skeletal muscle than in the liver.
Skeletal muscle accounts for 75% of glucose regulation in the
body and therefore it has a remarkable impact on blood glucose
homeostasis. It is established that type 2 diabetes mellitus is
characterized by insulin resistance, which results in lower levels of
blood glucose uptake into target tissues. Consequently, blood
glucose levels increase and more insulin is released producing
hyperinsulinaemia, which is manifested early in type 2 diabetes.
The effect of BPA on skeletal muscle may be direct on myocytes or
a consequence of the higher insulin release from b-cells produced
by BPA, or both. Several studies have demonstrated that the
hypersecretion of insulin is a primary defect of type 2 diabetes and
that insulin resistance develops secondarily to chronic hyperinsu-
linaemia [43–46]. Indeed, the persistance of chronic physiological
Figure 3. BPA treatment leads to increased IRS-1 protein in basal conditions and alters insulin signaling in insulin-stimulated
conditions in skeletal muscle.( A) Total IRS-1 protein expression levels (n=5). (B) Akt protein expression (n=4). a-tubulin was used as an internal
control. (C) IR tyrosine phosphorylation after insulin stimulation in vehicle and BPA treated animals (n=5–7), (D) Akt phosphorylation (Ser
473)( n=5 –
7) and (E) Akt phosphorylation (Thr
308) in the same conditions as panel C (n=4–5) (F) ERK1/2 phosphorylation (n=4–6). Statistical differences were
determined by Student’s t test *, p,0.05. Data are expressed as mean 6S.E.M.
doi:10.1371/journal.pone.0033814.g003
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insulin resistance in healthy subjects with normal glucose tolerance
[46]. Therefore it is plausible that the hyperstimulation of b-cells
produced by BPA may result in producing insulin resistance in
muscle and liver. This does not rule out a direct effect of BPA on
peripheral tissues. No direct effect on insulin signalling has been
yet described in neither the skeletal muscle nor the liver, but high
doses of BPA in the micromolar range has been shown to affect
leptin synthesis, to downregulate glucose transporters in adipocytes
and enhance lipid accumulation in the liver [47–49].
Thus, the present work demonstrates that low doses of the
environmental estrogen BPA in mice reduces overall energy
metabolism and leads to impairments on insulin action in
peripheral tissues, mainly in the skeletal muscle. These actions
are triggered at BPA levels close to the tolerable daily intake (TDI)
of 50 mg/kg/day set by the US-EPA and the EFSA. The TDI was
calculated by decreasing 1000 fold the lowest observed adverse
effect level (LOAEL) of 50 mg/kg/day. It could be argue that the
route of administration in the present work is subcutaneous (s.c.)
injection while the main route of human exposure is ingestion. We
used s.c. injection because we need to know exactly the
administered doses in order to properly perform mechanistic
studies. However, it must be noted that we previously published
that oral administration of BPA at exactly the same doses used in
the present work produced insulin resistance, as manifested by
alteration of insulin tolerance test [15]. Moreover, a previous study
by Prins et al [50] stated that ‘‘…. despite differences in BPA
metabolism, clearance and excretion mechanisms that diverge
between rodents and humans and despite differences in BPA
pharmacokinetics in route of exposure, the s.c. delivery of BPA
employed by our laboratory provides an internal dose and tissue
bioavailability that models internal human levels’’. Therefore the
results presented in this work may be relevant to humans.
During the recent years results have accumulated that indicate
BPA effects at lower exposures [6]. New pharmacokinetics
experiments performed in Rhesus monkeys, assuming a similar
metabolism to humans, point towards a BPA exposure as high as
500 mg/kg/day. Moreover, epidemiological studies clearly associ-
ate BPA levels in urine with risk of type 2 diabetes [7,51] and
remarkably, with insulin resistance in individuals with normal
body mass index [8]. Taken together with the fact that BPA
exposure is widespread, bisphenol-A can thus be considered as a
risk factor for type-2 diabetes.
Supporting Information
Figure S1 Body weight of mice treated with vehicle or
BPA for 8 days (n=8).
(TIF)
Figure S2 Total PI3K (p85) protein expression. A) Total
PI3K regulatory subunit (p85) protein expression (n=5). B) Total
PI3K regulatory subunit (p85) protein expression (n=4).
(TIF)
Figure S3 Pyruvate Tolerance Test. Mice received an
intraperitoneal injection of sodium pyruvate (2 g/Kg body weight)
diluted in saline after a 16 hour fast. Blood glucose was then
determined at the indicated time points (n=8–9).
(TIF)
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